American Shared Hospital Services (AMS) Stock Competitors & Peer Comparison
See (AMS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AMS | $1.35 | -6.90% | 8.9M | -6.14 | -$0.22 | N/A |
| HCA | $367.35 | -0.97% | 81.5B | 12.65 | $29.03 | +0.81% |
| THC | $163.60 | -3.82% | 14.1B | 8.51 | $19.23 | N/A |
| SOLV | $76.43 | +0.78% | 13.2B | 9.36 | $8.17 | N/A |
| DVA | $187.89 | -1.01% | 12.1B | 18.10 | $10.38 | N/A |
| FMS | $20.55 | -2.33% | 11B | 10.82 | $1.90 | +4.21% |
| EHC | $101.55 | -1.15% | 10.1B | 17.39 | $5.84 | +0.73% |
| ENSG | $165.70 | +0.42% | 9.7B | 26.99 | $6.14 | +0.15% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
| UHS | $142.55 | -1.48% | 8.9B | 5.96 | $23.95 | +0.56% |
Stock Comparison
AMS vs HCA Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, HCA has a market cap of 81.5B. Regarding current trading prices, AMS is priced at $1.35, while HCA trades at $367.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas HCA's P/E ratio is 12.65. In terms of profitability, AMS's ROE is -0.06%, compared to HCA's ROE of -1.23%. Regarding short-term risk, AMS is more volatile compared to HCA. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check HCA's competition here
AMS vs THC Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, THC has a market cap of 14.1B. Regarding current trading prices, AMS is priced at $1.35, while THC trades at $163.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas THC's P/E ratio is 8.51. In terms of profitability, AMS's ROE is -0.06%, compared to THC's ROE of +0.41%. Regarding short-term risk, AMS is more volatile compared to THC. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check THC's competition here
AMS vs SOLV Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, SOLV has a market cap of 13.2B. Regarding current trading prices, AMS is priced at $1.35, while SOLV trades at $76.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas SOLV's P/E ratio is 9.36. In terms of profitability, AMS's ROE is -0.06%, compared to SOLV's ROE of +0.31%. Regarding short-term risk, AMS is more volatile compared to SOLV. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check SOLV's competition here
AMS vs DVA Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, DVA has a market cap of 12.1B. Regarding current trading prices, AMS is priced at $1.35, while DVA trades at $187.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas DVA's P/E ratio is 18.10. In terms of profitability, AMS's ROE is -0.06%, compared to DVA's ROE of -1.33%. Regarding short-term risk, AMS is more volatile compared to DVA. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check DVA's competition here
AMS vs FMS Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, FMS has a market cap of 11B. Regarding current trading prices, AMS is priced at $1.35, while FMS trades at $20.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas FMS's P/E ratio is 10.82. In terms of profitability, AMS's ROE is -0.06%, compared to FMS's ROE of +0.07%. Regarding short-term risk, AMS is more volatile compared to FMS. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check FMS's competition here
AMS vs EHC Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, EHC has a market cap of 10.1B. Regarding current trading prices, AMS is priced at $1.35, while EHC trades at $101.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas EHC's P/E ratio is 17.39. In terms of profitability, AMS's ROE is -0.06%, compared to EHC's ROE of +0.25%. Regarding short-term risk, AMS is more volatile compared to EHC. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check EHC's competition here
AMS vs ENSG Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, ENSG has a market cap of 9.7B. Regarding current trading prices, AMS is priced at $1.35, while ENSG trades at $165.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas ENSG's P/E ratio is 26.99. In terms of profitability, AMS's ROE is -0.06%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, AMS is more volatile compared to ENSG. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check ENSG's competition here
AMS vs OSH Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, AMS is priced at $1.35, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas OSH's P/E ratio is -17.65. In terms of profitability, AMS's ROE is -0.06%, compared to OSH's ROE of +4.64%. Regarding short-term risk, AMS is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check OSH's competition here
AMS vs UHS Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, UHS has a market cap of 8.9B. Regarding current trading prices, AMS is priced at $1.35, while UHS trades at $142.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas UHS's P/E ratio is 5.96. In terms of profitability, AMS's ROE is -0.06%, compared to UHS's ROE of +0.21%. Regarding short-term risk, AMS is more volatile compared to UHS. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check UHS's competition here
AMS vs CHE Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, CHE has a market cap of 5.5B. Regarding current trading prices, AMS is priced at $1.35, while CHE trades at $417.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas CHE's P/E ratio is 22.75. In terms of profitability, AMS's ROE is -0.06%, compared to CHE's ROE of +0.25%. Regarding short-term risk, AMS is more volatile compared to CHE. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check CHE's competition here
AMS vs LHCG Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, AMS is priced at $1.35, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas LHCG's P/E ratio is 82.83. In terms of profitability, AMS's ROE is -0.06%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, AMS is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check LHCG's competition here
AMS vs MMED Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, MMED has a market cap of 3.5B. Regarding current trading prices, AMS is priced at $1.35, while MMED trades at $12.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas MMED's P/E ratio is -9.69. In terms of profitability, AMS's ROE is -0.06%, compared to MMED's ROE of -0.09%. Regarding short-term risk, AMS is more volatile compared to MMED. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check MMED's competition here
AMS vs AMED Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, AMS is priced at $1.35, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas AMED's P/E ratio is 39.30. In terms of profitability, AMS's ROE is -0.06%, compared to AMED's ROE of +0.09%. Regarding short-term risk, AMS is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check AMED's competition here
AMS vs OPCH Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, OPCH has a market cap of 3.2B. Regarding current trading prices, AMS is priced at $1.35, while OPCH trades at $20.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas OPCH's P/E ratio is 16.05. In terms of profitability, AMS's ROE is -0.06%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, AMS is more volatile compared to OPCH. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check OPCH's competition here
AMS vs LFST Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, LFST has a market cap of 3B. Regarding current trading prices, AMS is priced at $1.35, while LFST trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas LFST's P/E ratio is 129.33. In terms of profitability, AMS's ROE is -0.06%, compared to LFST's ROE of +0.02%. Regarding short-term risk, AMS is more volatile compared to LFST. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check LFST's competition here
AMS vs BKD Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, BKD has a market cap of 2.9B. Regarding current trading prices, AMS is priced at $1.35, while BKD trades at $12.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas BKD's P/E ratio is -13.85. In terms of profitability, AMS's ROE is -0.06%, compared to BKD's ROE of +401.19%. Regarding short-term risk, AMS is more volatile compared to BKD. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check BKD's competition here
AMS vs NHC Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, NHC has a market cap of 2.9B. Regarding current trading prices, AMS is priced at $1.35, while NHC trades at $183.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas NHC's P/E ratio is 23.28. In terms of profitability, AMS's ROE is -0.06%, compared to NHC's ROE of +0.12%. Regarding short-term risk, AMS is more volatile compared to NHC. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check NHC's competition here
AMS vs ACHC Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, ACHC has a market cap of 2.2B. Regarding current trading prices, AMS is priced at $1.35, while ACHC trades at $24.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas ACHC's P/E ratio is -2.00. In terms of profitability, AMS's ROE is -0.06%, compared to ACHC's ROE of -0.44%. Regarding short-term risk, AMS is more volatile compared to ACHC. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check ACHC's competition here
AMS vs SEM Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, SEM has a market cap of 2B. Regarding current trading prices, AMS is priced at $1.35, while SEM trades at $16.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas SEM's P/E ratio is 15.43. In terms of profitability, AMS's ROE is -0.06%, compared to SEM's ROE of +0.08%. Regarding short-term risk, AMS is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check SEM's competition here
AMS vs AMEH Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, AMS is priced at $1.35, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas AMEH's P/E ratio is 39.25. In terms of profitability, AMS's ROE is -0.06%, compared to AMEH's ROE of +0.04%. Regarding short-term risk, AMS is more volatile compared to AMEH. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check AMEH's competition here
AMS vs ASTH Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, ASTH has a market cap of 1.8B. Regarding current trading prices, AMS is priced at $1.35, while ASTH trades at $36.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas ASTH's P/E ratio is 60.49. In terms of profitability, AMS's ROE is -0.06%, compared to ASTH's ROE of +0.04%. Regarding short-term risk, AMS is more volatile compared to ASTH. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check ASTH's competition here
AMS vs SGRY Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, SGRY has a market cap of 1.8B. Regarding current trading prices, AMS is priced at $1.35, while SGRY trades at $13.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas SGRY's P/E ratio is -23.34. In terms of profitability, AMS's ROE is -0.06%, compared to SGRY's ROE of -0.04%. Regarding short-term risk, AMS is more volatile compared to SGRY. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check SGRY's competition here
AMS vs MD Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, MD has a market cap of 1.8B. Regarding current trading prices, AMS is priced at $1.35, while MD trades at $21.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas MD's P/E ratio is 10.56. In terms of profitability, AMS's ROE is -0.06%, compared to MD's ROE of +0.20%. Regarding short-term risk, AMS is more volatile compared to MD. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check MD's competition here
AMS vs ADUS Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, ADUS has a market cap of 1.7B. Regarding current trading prices, AMS is priced at $1.35, while ADUS trades at $90.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas ADUS's P/E ratio is 16.69. In terms of profitability, AMS's ROE is -0.06%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, AMS is more volatile compared to ADUS. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check ADUS's competition here
AMS vs AGL Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, AGL has a market cap of 1.4B. Regarding current trading prices, AMS is priced at $1.35, while AGL trades at $86.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas AGL's P/E ratio is -3.83. In terms of profitability, AMS's ROE is -0.06%, compared to AGL's ROE of -1.46%. Regarding short-term risk, AMS is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check AGL's competition here
AMS vs AVAH Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, AVAH has a market cap of 1.4B. Regarding current trading prices, AMS is priced at $1.35, while AVAH trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas AVAH's P/E ratio is 5.34. In terms of profitability, AMS's ROE is -0.06%, compared to AVAH's ROE of +2.41%. Regarding short-term risk, AMS is less volatile compared to AVAH. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check AVAH's competition here
AMS vs HCSG Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, HCSG has a market cap of 1.4B. Regarding current trading prices, AMS is priced at $1.35, while HCSG trades at $20.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas HCSG's P/E ratio is 21.31. In terms of profitability, AMS's ROE is -0.06%, compared to HCSG's ROE of +0.14%. Regarding short-term risk, AMS is more volatile compared to HCSG. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check HCSG's competition here
AMS vs ARDT Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, ARDT has a market cap of 1.3B. Regarding current trading prices, AMS is priced at $1.35, while ARDT trades at $9.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas ARDT's P/E ratio is 9.76. In terms of profitability, AMS's ROE is -0.06%, compared to ARDT's ROE of +0.09%. Regarding short-term risk, AMS is more volatile compared to ARDT. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check ARDT's competition here
AMS vs CMPS Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, CMPS has a market cap of 1.3B. Regarding current trading prices, AMS is priced at $1.35, while CMPS trades at $13.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas CMPS's P/E ratio is -4.25. In terms of profitability, AMS's ROE is -0.06%, compared to CMPS's ROE of -1.51%. Regarding short-term risk, AMS is more volatile compared to CMPS. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check CMPS's competition here
AMS vs BKDT Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, AMS is priced at $1.35, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas BKDT's P/E ratio is N/A. In terms of profitability, AMS's ROE is -0.06%, compared to BKDT's ROE of +401.19%. Regarding short-term risk, AMS is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check BKDT's competition here
AMS vs AMN Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, AMN has a market cap of 1.2B. Regarding current trading prices, AMS is priced at $1.35, while AMN trades at $30.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas AMN's P/E ratio is -35.22. In terms of profitability, AMS's ROE is -0.06%, compared to AMN's ROE of -0.05%. Regarding short-term risk, AMS is more volatile compared to AMN. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check AMN's competition here
AMS vs PNTG Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, PNTG has a market cap of 1.1B. Regarding current trading prices, AMS is priced at $1.35, while PNTG trades at $30.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas PNTG's P/E ratio is 35.87. In terms of profitability, AMS's ROE is -0.06%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, AMS is more volatile compared to PNTG. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check PNTG's competition here
AMS vs INNV Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, INNV has a market cap of 980M. Regarding current trading prices, AMS is priced at $1.35, while INNV trades at $7.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas INNV's P/E ratio is -90.25. In terms of profitability, AMS's ROE is -0.06%, compared to INNV's ROE of -0.09%. Regarding short-term risk, AMS is more volatile compared to INNV. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check INNV's competition here
AMS vs USPH Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, USPH has a market cap of 951.9M. Regarding current trading prices, AMS is priced at $1.35, while USPH trades at $62.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas USPH's P/E ratio is 125.10. In terms of profitability, AMS's ROE is -0.06%, compared to USPH's ROE of +0.00%. Regarding short-term risk, AMS is more volatile compared to USPH. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check USPH's competition here
AMS vs TALK Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, TALK has a market cap of 874.4M. Regarding current trading prices, AMS is priced at $1.35, while TALK trades at $5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas TALK's P/E ratio is 130.50. In terms of profitability, AMS's ROE is -0.06%, compared to TALK's ROE of +0.01%. Regarding short-term risk, AMS is more volatile compared to TALK. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check TALK's competition here
AMS vs FSHCX Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, FSHCX has a market cap of 816.7M. Regarding current trading prices, AMS is priced at $1.35, while FSHCX trades at $104.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas FSHCX's P/E ratio is N/A. In terms of profitability, AMS's ROE is -0.06%, compared to FSHCX's ROE of N/A. Regarding short-term risk, AMS is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check FSHCX's competition here
AMS vs EHAB Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, EHAB has a market cap of 706.9M. Regarding current trading prices, AMS is priced at $1.35, while EHAB trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas EHAB's P/E ratio is -197.14. In terms of profitability, AMS's ROE is -0.06%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, AMS is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check EHAB's competition here
AMS vs SNDA Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, SNDA has a market cap of 673.4M. Regarding current trading prices, AMS is priced at $1.35, while SNDA trades at $33.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas SNDA's P/E ratio is -5.77. In terms of profitability, AMS's ROE is -0.06%, compared to SNDA's ROE of -0.35%. Regarding short-term risk, AMS is more volatile compared to SNDA. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check SNDA's competition here
AMS vs GMRS Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, GMRS has a market cap of 484.8M. Regarding current trading prices, AMS is priced at $1.35, while GMRS trades at $10.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas GMRS's P/E ratio is 66.47. In terms of profitability, AMS's ROE is -0.06%, compared to GMRS's ROE of N/A. Regarding short-term risk, AMS is less volatile compared to GMRS. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check GMRS's competition here
AMS vs TOI Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, TOI has a market cap of 458.9M. Regarding current trading prices, AMS is priced at $1.35, while TOI trades at $4.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas TOI's P/E ratio is -13.11. In terms of profitability, AMS's ROE is -0.06%, compared to TOI's ROE of +3.27%. Regarding short-term risk, AMS is more volatile compared to TOI. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check TOI's competition here
AMS vs MCTA Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, AMS is priced at $1.35, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas MCTA's P/E ratio is 419.36. In terms of profitability, AMS's ROE is -0.06%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, AMS is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check MCTA's competition here
AMS vs CCRN Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, CCRN has a market cap of 423.2M. Regarding current trading prices, AMS is priced at $1.35, while CCRN trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas CCRN's P/E ratio is -4.29. In terms of profitability, AMS's ROE is -0.06%, compared to CCRN's ROE of -0.27%. Regarding short-term risk, AMS is more volatile compared to CCRN. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check CCRN's competition here
AMS vs CYH Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, CYH has a market cap of 391M. Regarding current trading prices, AMS is priced at $1.35, while CYH trades at $2.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas CYH's P/E ratio is 0.81. In terms of profitability, AMS's ROE is -0.06%, compared to CYH's ROE of +0.06%. Regarding short-term risk, AMS is more volatile compared to CYH. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check CYH's competition here
AMS vs AIRS Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, AIRS has a market cap of 368.2M. Regarding current trading prices, AMS is priced at $1.35, while AIRS trades at $5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas AIRS's P/E ratio is -30.71. In terms of profitability, AMS's ROE is -0.06%, compared to AIRS's ROE of -0.12%. Regarding short-term risk, AMS is more volatile compared to AIRS. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check AIRS's competition here
AMS vs AUNA Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, AUNA has a market cap of 335.3M. Regarding current trading prices, AMS is priced at $1.35, while AUNA trades at $4.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas AUNA's P/E ratio is 16.78. In terms of profitability, AMS's ROE is -0.06%, compared to AUNA's ROE of +0.04%. Regarding short-term risk, AMS is more volatile compared to AUNA. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check AUNA's competition here
AMS vs AONC Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, AONC has a market cap of 292.5M. Regarding current trading prices, AMS is priced at $1.35, while AONC trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas AONC's P/E ratio is -11.24. In terms of profitability, AMS's ROE is -0.06%, compared to AONC's ROE of +0.06%. Regarding short-term risk, AMS is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check AONC's competition here
AMS vs CSU Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, AMS is priced at $1.35, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas CSU's P/E ratio is 0.67. In terms of profitability, AMS's ROE is -0.06%, compared to CSU's ROE of -0.51%. Regarding short-term risk, AMS is more volatile compared to CSU. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check CSU's competition here
AMS vs JYNT Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, JYNT has a market cap of 123.6M. Regarding current trading prices, AMS is priced at $1.35, while JYNT trades at $8.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas JYNT's P/E ratio is 96.33. In terms of profitability, AMS's ROE is -0.06%, compared to JYNT's ROE of +0.17%. Regarding short-term risk, AMS is more volatile compared to JYNT. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check JYNT's competition here
AMS vs NAKAW Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, NAKAW has a market cap of 116.4M. Regarding current trading prices, AMS is priced at $1.35, while NAKAW trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas NAKAW's P/E ratio is N/A. In terms of profitability, AMS's ROE is -0.06%, compared to NAKAW's ROE of -0.85%. Regarding short-term risk, AMS is less volatile compared to NAKAW. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check NAKAW's competition here
AMS vs FVE Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, AMS is priced at $1.35, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas FVE's P/E ratio is -5.64. In terms of profitability, AMS's ROE is -0.06%, compared to FVE's ROE of -0.15%. Regarding short-term risk, AMS is more volatile compared to FVE. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check FVE's competition here
AMS vs KDLYW Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, AMS is priced at $1.35, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas KDLYW's P/E ratio is N/A. In terms of profitability, AMS's ROE is -0.06%, compared to KDLYW's ROE of -0.85%. Regarding short-term risk, AMS is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check KDLYW's competition here
AMS vs BTMD Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, BTMD has a market cap of 94.8M. Regarding current trading prices, AMS is priced at $1.35, while BTMD trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas BTMD's P/E ratio is 5.00. In terms of profitability, AMS's ROE is -0.06%, compared to BTMD's ROE of -0.23%. Regarding short-term risk, AMS is more volatile compared to BTMD. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check BTMD's competition here
AMS vs DCGO Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, DCGO has a market cap of 62M. Regarding current trading prices, AMS is priced at $1.35, while DCGO trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas DCGO's P/E ratio is -0.33. In terms of profitability, AMS's ROE is -0.06%, compared to DCGO's ROE of -0.89%. Regarding short-term risk, AMS is more volatile compared to DCGO. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check DCGO's competition here
AMS vs ALR Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, AMS is priced at $1.35, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas ALR's P/E ratio is -1.11. In terms of profitability, AMS's ROE is -0.06%, compared to ALR's ROE of -0.15%. Regarding short-term risk, AMS is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check ALR's competition here
AMS vs PIII Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, PIII has a market cap of 42.1M. Regarding current trading prices, AMS is priced at $1.35, while PIII trades at $12.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas PIII's P/E ratio is -0.33. In terms of profitability, AMS's ROE is -0.06%, compared to PIII's ROE of +1.85%. Regarding short-term risk, AMS is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check PIII's competition here
AMS vs IMAC Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, AMS is priced at $1.35, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas IMAC's P/E ratio is -2.27. In terms of profitability, AMS's ROE is -0.06%, compared to IMAC's ROE of +1183.61%. Regarding short-term risk, AMS is more volatile compared to IMAC. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check IMAC's competition here
AMS vs CCEL Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, CCEL has a market cap of 28.7M. Regarding current trading prices, AMS is priced at $1.35, while CCEL trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas CCEL's P/E ratio is -11.12. In terms of profitability, AMS's ROE is -0.06%, compared to CCEL's ROE of +0.16%. Regarding short-term risk, AMS is less volatile compared to CCEL. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check CCEL's competition here
AMS vs CANO-WT Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, AMS is priced at $1.35, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, AMS's ROE is -0.06%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, AMS is less volatile compared to CANO-WT. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check CANO-WT's competition here
AMS vs AIH Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, AMS is priced at $1.35, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas AIH's P/E ratio is -2.78. In terms of profitability, AMS's ROE is -0.06%, compared to AIH's ROE of +1.16%. Regarding short-term risk, AMS is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check AIH's competition here
AMS vs CANO Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, AMS is priced at $1.35, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas CANO's P/E ratio is -0.01. In terms of profitability, AMS's ROE is -0.06%, compared to CANO's ROE of -1.49%. Regarding short-term risk, AMS is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check CANO's competition here
AMS vs FTRP Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, AMS is priced at $1.35, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas FTRP's P/E ratio is -1.22. In terms of profitability, AMS's ROE is -0.06%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, AMS is more volatile compared to FTRP. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check FTRP's competition here
AMS vs MODV Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, AMS is priced at $1.35, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas MODV's P/E ratio is -0.03. In terms of profitability, AMS's ROE is -0.06%, compared to MODV's ROE of +1.84%. Regarding short-term risk, AMS is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check MODV's competition here
AMS vs GBNH Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, AMS is priced at $1.35, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas GBNH's P/E ratio is -0.06. In terms of profitability, AMS's ROE is -0.06%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, AMS is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check GBNH's competition here
AMS vs SYRA Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, SYRA has a market cap of 5.4M. Regarding current trading prices, AMS is priced at $1.35, while SYRA trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas SYRA's P/E ratio is -24.00. In terms of profitability, AMS's ROE is -0.06%, compared to SYRA's ROE of -0.08%. Regarding short-term risk, AMS is more volatile compared to SYRA. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check SYRA's competition here
AMS vs RHE-PA Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, AMS is priced at $1.35, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, AMS's ROE is -0.06%, compared to RHE-PA's ROE of +2.11%. Regarding short-term risk, AMS is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check RHE-PA's competition here
AMS vs RHE Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, AMS is priced at $1.35, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas RHE's P/E ratio is -1.79. In terms of profitability, AMS's ROE is -0.06%, compared to RHE's ROE of -0.36%. Regarding short-term risk, AMS is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check RHE's competition here
AMS vs TOIIW Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, TOIIW has a market cap of 4.8M. Regarding current trading prices, AMS is priced at $1.35, while TOIIW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas TOIIW's P/E ratio is N/A. In terms of profitability, AMS's ROE is -0.06%, compared to TOIIW's ROE of +3.27%. Regarding short-term risk, AMS is less volatile compared to TOIIW. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check TOIIW's competition here
AMS vs ATIP Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, ATIP has a market cap of 3M. Regarding current trading prices, AMS is priced at $1.35, while ATIP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas ATIP's P/E ratio is -0.03. In terms of profitability, AMS's ROE is -0.06%, compared to ATIP's ROE of +2.05%. Regarding short-term risk, AMS is less volatile compared to ATIP. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check ATIP's competition here
AMS vs IMACW Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, AMS is priced at $1.35, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas IMACW's P/E ratio is N/A. In terms of profitability, AMS's ROE is -0.06%, compared to IMACW's ROE of +1.05%. Regarding short-term risk, AMS is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check IMACW's competition here
AMS vs CCM Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, CCM has a market cap of 694.6K. Regarding current trading prices, AMS is priced at $1.35, while CCM trades at $4.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas CCM's P/E ratio is -1.52. In terms of profitability, AMS's ROE is -0.06%, compared to CCM's ROE of +0.07%. Regarding short-term risk, AMS is more volatile compared to CCM. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check CCM's competition here
AMS vs TALKW Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, TALKW has a market cap of 686.8K. Regarding current trading prices, AMS is priced at $1.35, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas TALKW's P/E ratio is N/A. In terms of profitability, AMS's ROE is -0.06%, compared to TALKW's ROE of +0.01%. Regarding short-term risk, AMS is less volatile compared to TALKW. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check TALKW's competition here
AMS vs MNDR Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, MNDR has a market cap of 657.8K. Regarding current trading prices, AMS is priced at $1.35, while MNDR trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas MNDR's P/E ratio is -0.31. In terms of profitability, AMS's ROE is -0.06%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, AMS is more volatile compared to MNDR. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check MNDR's competition here
AMS vs NIVF Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, NIVF has a market cap of 527.2K. Regarding current trading prices, AMS is priced at $1.35, while NIVF trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas NIVF's P/E ratio is 0.03. In terms of profitability, AMS's ROE is -0.06%, compared to NIVF's ROE of +0.33%. Regarding short-term risk, AMS is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check NIVF's competition here
AMS vs NVOS Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, NVOS has a market cap of 394.6K. Regarding current trading prices, AMS is priced at $1.35, while NVOS trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas NVOS's P/E ratio is -0.02. In terms of profitability, AMS's ROE is -0.06%, compared to NVOS's ROE of -0.81%. Regarding short-term risk, AMS is less volatile compared to NVOS. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check NVOS's competition here
AMS vs BACK Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, BACK has a market cap of 227.1K. Regarding current trading prices, AMS is priced at $1.35, while BACK trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas BACK's P/E ratio is -0.02. In terms of profitability, AMS's ROE is -0.06%, compared to BACK's ROE of +1.05%. Regarding short-term risk, AMS is less volatile compared to BACK. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check BACK's competition here
AMS vs PIIIW Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, PIIIW has a market cap of 49K. Regarding current trading prices, AMS is priced at $1.35, while PIIIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas PIIIW's P/E ratio is -0.01. In terms of profitability, AMS's ROE is -0.06%, compared to PIIIW's ROE of +1.85%. Regarding short-term risk, AMS is less volatile compared to PIIIW. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check PIIIW's competition here
AMS vs NIVFW Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, NIVFW has a market cap of 44.3K. Regarding current trading prices, AMS is priced at $1.35, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas NIVFW's P/E ratio is N/A. In terms of profitability, AMS's ROE is -0.06%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, AMS is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check NIVFW's competition here
AMS vs IONM Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, IONM has a market cap of 1.6K. Regarding current trading prices, AMS is priced at $1.35, while IONM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas IONM's P/E ratio is N/A. In terms of profitability, AMS's ROE is -0.06%, compared to IONM's ROE of +5.28%. Regarding short-term risk, AMS is more volatile compared to IONM. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check IONM's competition here
AMS vs KND Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, KND has a market cap of 0. Regarding current trading prices, AMS is priced at $1.35, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas KND's P/E ratio is N/A. In terms of profitability, AMS's ROE is -0.06%, compared to KND's ROE of -0.53%. Regarding short-term risk, AMS is more volatile compared to KND. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check KND's competition here
AMS vs TVTY Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, TVTY has a market cap of 0. Regarding current trading prices, AMS is priced at $1.35, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas TVTY's P/E ratio is 19.06. In terms of profitability, AMS's ROE is -0.06%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, AMS is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check TVTY's competition here
AMS vs DCGOW Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, AMS is priced at $1.35, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas DCGOW's P/E ratio is N/A. In terms of profitability, AMS's ROE is -0.06%, compared to DCGOW's ROE of -0.89%. Regarding short-term risk, AMS is more volatile compared to DCGOW. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check DCGOW's competition here
AMS vs NFH Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, NFH has a market cap of 0. Regarding current trading prices, AMS is priced at $1.35, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas NFH's P/E ratio is -19.75. In terms of profitability, AMS's ROE is -0.06%, compared to NFH's ROE of -0.06%. Regarding short-term risk, AMS is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check NFH's competition here
AMS vs HNGR Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, HNGR has a market cap of 0. Regarding current trading prices, AMS is priced at $1.35, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas HNGR's P/E ratio is 19.71. In terms of profitability, AMS's ROE is -0.06%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, AMS is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check HNGR's competition here
AMS vs AFAM Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, AFAM has a market cap of 0. Regarding current trading prices, AMS is priced at $1.35, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas AFAM's P/E ratio is N/A. In terms of profitability, AMS's ROE is -0.06%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, AMS is more volatile compared to AFAM. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check AFAM's competition here
AMS vs SLHGP Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, AMS is priced at $1.35, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, AMS's ROE is -0.06%, compared to SLHGP's ROE of -0.48%. Regarding short-term risk, AMS is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check SLHGP's competition here
AMS vs TLMD Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, TLMD has a market cap of 0. Regarding current trading prices, AMS is priced at $1.35, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas TLMD's P/E ratio is -1.60. In terms of profitability, AMS's ROE is -0.06%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, AMS is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check TLMD's competition here
AMS vs SLHG Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, SLHG has a market cap of 0. Regarding current trading prices, AMS is priced at $1.35, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas SLHG's P/E ratio is -1.48. In terms of profitability, AMS's ROE is -0.06%, compared to SLHG's ROE of N/A. Regarding short-term risk, AMS is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check SLHG's competition here
AMS vs DVCR Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, DVCR has a market cap of 0. Regarding current trading prices, AMS is priced at $1.35, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas DVCR's P/E ratio is 28.34. In terms of profitability, AMS's ROE is -0.06%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, AMS is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check DVCR's competition here
AMS vs ATIP-WT Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, AMS is priced at $1.35, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, AMS's ROE is -0.06%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, AMS is less volatile compared to ATIP-WT. This indicates potentially lower risk in terms of short-term price fluctuations for AMS.Check ATIP-WT's competition here
AMS vs TLMDW Comparison June 2026
AMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMS stands at 8.9M. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, AMS is priced at $1.35, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMS currently has a P/E ratio of -6.14, whereas TLMDW's P/E ratio is N/A. In terms of profitability, AMS's ROE is -0.06%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, AMS is more volatile compared to TLMDW. This indicates potentially higher risk in terms of short-term price fluctuations for AMS.Check TLMDW's competition here